Welcome to our dedicated page for Syra Health SEC filings (Ticker: SYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Syra Health’s regulatory disclosures can feel like piecing together a public-health puzzle. The company juggles population health analytics, digital therapeutics such as the Syrenity app, and contract-driven workforce programs—each layer adding complexity to every 10-K risk factor and 8-K update. Investors searching "Syra Health SEC filings explained simply" or "Syra Health insider trading Form 4 transactions" often spend hours locating the numbers that matter.
Stock Titan’s AI bridges that gap in seconds. When a new "Syra Health quarterly earnings report 10-Q filing" hits EDGAR, our engine produces instant summaries, highlights reimbursement footnotes, and sends "Syra Health Form 4 insider transactions real-time" alerts. Need a "Syra Health annual report 10-K simplified" overview, a "Syra Health proxy statement executive compensation" digest, or a "Syra Health 8-K material events explained" snapshot? You’ll get them while the documents are still syncing, complete with red-line changes and expert context.
Practical use cases span monitoring "Syra Health executive stock transactions Form 4" before material announcements to comparing quarter-over-quarter margins via our "Syra Health earnings report filing analysis" dashboards. Every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A, Form 4—is archived, searchable, and paired with AI-powered highlights that surface segment KPIs, population-health metrics, and digital-health adoption rates without wading through 200 pages. Understand Syra Health SEC documents with AI, make faster decisions, and stay ahead of every disclosure.
Syra Health Corp proxy excerpts show board composition, director changes, equity holdings and compensation details. The company has an insider trading policy for employees, officers, directors, consultants and related parties. Several directors and executives appear in compensation tables showing 2023 and 2024 total compensation in the low hundreds of thousands, with amounts such as $319,629, $200,730 and $171,291 reported for specific individuals. The disclosure lists equity awards and outstanding option counts for directors and significant holders, and notes audit-related fees of $17,000 and total fees of $92,000 and $114,755. The filing also records personnel changes: Sandeep Allam was reported deceased on January 15, 2025, Andrew Dahlem resigned the board on April 25, 2025, and Deepika Vuppalanchi resigned on July 28, 2025. The company states it does not have a written policy governing timing of option grants around material nonpublic information.
FAQ
What is the current stock price of Syra Health (SYRA)?
What is the market cap of Syra Health (SYRA)?
